Prof. Yu Wang 王宇
Chief Physician, Professor
Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Surgical and comprehensive treatment of head and neck tumors, including thyroid, salivary gland, oral, laryngeal, and soft tissue cancers. Focuses on endoscopic/robotic surgery, function-preserving procedures, and post-operative reconstruction.
Dr. Wang is Director of Head and Neck Surgery at Fudan University Shanghai Cancer Center. Dr. Wang earned a master’s degree from Shanghai Medical University in 2000 and a PhD from Fudan University in 2005, with further training at MD Anderson Cancer Center in 2007. Dr. Wang has led or participated in over 20 national and provincial research projects and published more than 60 papers.
Professional roles
- Vice Chair, Thyroid Tumor Professional Committee, China Anti-Cancer Association (2022–present)
- Vice Chair, Head and Neck Tumor Professional Committee, China Medical Education Association (2022–present)
- Member, Thyroid Cancer Quality Control Expert Committee, National Cancer Center (2021–present)
- Standing Committee Member, Head and Neck Tumor Professional Committee, China Anti-Cancer Association (2022–present)
Name order: in Chinese the family name comes first (Wang Yu). Papers usually list the name as Yu Wang or Wang Y.
Selected publications
194 papers on PubMed matched by name and affiliation; 41 as first or senior author since 2016. Most recent first- or senior-author papers:
- Cell Rep Med, 2026 (senior author): Development and validation of a serum peptidomic signature for early detection of asymptomatic ovarian cancer: A multi-center prospective study. PubMed 42664958
- BMC Public Health, 2026 (first author): Effectiveness and cost-effectiveness of general health checks in adults: A systematic review. PubMed 42414985
- Sci Rep, 2026 (first author): The KRT15 and KRT81 complex promotes lenvatinib resistance in thyroid cancer by upregulating DGKB mediated lipid metabolism. PubMed 41991644
- Mater Today Bio, 2026 (first author): Osteoimmunology uncovered: How macrophages and biomaterials revolutionize bone healing. PubMed 41560822
- JAMA Otolaryngol Head Neck Surg, 2026 (senior author): Do Updated Calcitonin Thresholds More Accurately Predict Lymph Node Metastasis in Medullary Thyroid Cancer?-Reply. PubMed 41231483
- Eur Thyroid J, 2025 (senior author): Personalized treatment of 95 poorly differentiated thyroid cancer/anaplastic thyroid cancer in 2019-2023. PubMed 41104970
- NPJ Digit Med, 2025 (senior author): Developing a thyroid cancer differentiation state classification system using deep residual networks and metabolic signature profiling. PubMed 40993300
- J Natl Compr Canc Netw, 2025 (senior author): Authors' Reply to the Letter to the Editor by Foote et al: Revisiting a "Revised Perspective on the American Joint Committee on Cancer's Staging System for Medullary Thyroid Cancer". PubMed 40930135
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion